MGBG: a highly active drug in relapsed or refractory AIDS-lymphoma (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

MGBG: a highly active drug in relapsed or refractory AIDS-lymphoma (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A11 1994. Unique Identifier : AIDSLINE ICDB/94600008
Levine AM; Weiss G; Tulpule A; Espina B; Anderson LJ; Boswell W; Esplin J; Von Hoff D; Univ. Southern Cal School Medicine, Los Angeles, CA

Abstract: Methyl-glyoxal-bisguanylhydrazone (MGBG) interferes with polyamine biosynthesis, thought important in the stabilization of DNA. Used initially in the early 1980s on a daily or weekly basis, response rates of 29-40% were seen in 'de novo' lymphoma, although toxicity (mucositis, vasculitis) was significant. With a long T1/2, good penetration into CSF, and relative lack of marrow toxicity, a dosing schedule of MGBG, 600 mg/m2 IV days 1, 8 and then every 2 wk was used in 10 male pts with refractory or relapsed AIDS-lymphoma. Median age was 41 yr (26-58). Median CD4 cells prior to MGBG was 117/dl (4-427); 80% had CD4s less than 200/dl. Four pts had AIDS prior to MGBG. Four pts had 1 prior regimen for AIDS-lymphoma, 4 had 2; 1 had 3; and 1 had 4 regimens prior to MGBG. High grade small noncleaved lymphoma was present in 6; 1 had B immunoblastic; others had intermediate grade. Stage IV was present in 9 (BM in 3; CNS in 2; lung in 5+ others). A median of 4+ doses of MGBG was administered (1-20 +). Toxicity was mild, consisting of flushing (N=9); tingling (N=8); euphoria (N=3); or somnolence (N=2) during infusion. Mild nausea, vomiting (N=4); fatigue (N=3); and neutropenia (N=3) were also seen. Response: CR was seen in 2, solid PR in 3, for response rate of 50% in these heavily pretreated pts. Quality of survival is excellent, and median duration survival since MGBG is 4.3 mo. We conclude: (1) MGBG is associated with 50% durable response rate in refractory AIDS-lymphoma; (2) Toxicity is mild; (3) Quality and quantity of survival have been positively impacted; (4) Study is on-going with additional pt entry.

Keywords: Adult Follow-Up Studies Human Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY Male Middle Age Mitoguazone/ADVERSE EFFECTS/*THERAPEUTIC USE Neoplasm Recurrence, Local/DRUG THERAPY/MORTALITY Neoplasm Staging Quality of Life Survival Rate ABSTRACT
940830
M9480790

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .